Recent Regulatory 8-K events
Recent 8-Ks about regulator actions, exchange notices, compliance events, and approvals.
-
Nasdaq to delist DAIC for failing $50M MVLS; company to appeal by Aug 13
-
Cycurion confirms Nasdaq hearing on Aug 20; stock still trading
-
Greenland Energy permitting for Jameson Land drilling extended to winter 2027
-
Intelligent Bio Solutions completes final clinical study; FDA 510(k) submission on track for H2 2026
-
Grove receives NYSE non-compliance notice for market cap/equity below $50M
-
Rocket One faces Nasdaq delisting notice for low bid price; joins Seagate Partner Program
-
SolarMax announces 1-for-12 reverse split effective Aug 13 to meet Nasdaq bid price rule
-
Netcapital granted extra 180-day Nasdaq compliance period; amends Vanquish notes
-
Lexaria Bioscience receives Nasdaq delisting notice but expects compliance via reverse split
-
CEA Industries regains Nasdaq annual-meeting compliance; matter closed
-
Clene reports biomarker analyses showing CNM-Au8 survival benefit in NfL responders for ALS NDA
-
Arcadia Biosciences receives Nasdaq delisting notice for bid price below $1.00
-
Triller regains Nasdaq compliance; bid price met $1.00 for 20 sessions
-
NusaTrip receives Nasdaq delisting notice; will not appeal, moves to OTC
-
Eightco receives Nasdaq delisting notice for bid price below $1.00
-
Neonode receives Nasdaq delisting notice for bid price below $1.00
-
First Guaranty Bank consents to FDIC/OFI order; Tier 1 leverage below required 9%
-
Avalanche Treasury (AVAT) gets Nasdaq delisting warnings for bid price and MVLS
-
Elutia receives Nasdaq delisting notice for bid price below $1.00
-
Elite Express regains Nasdaq minimum bid price compliance; matter closed
-
Barfresh gets Nasdaq MVLS delisting notice; CFO Lisa Roger to retire by Dec 31
-
Niki BioSolutions regains Nasdaq minimum bid price compliance
-
Giftify receives Nasdaq delisting notice for bid price below $1.00
-
NRx Pharmaceuticals FDA ANDA review: no drug deficiencies; packaging issue to resolve
-
FDA grants accelerated approval to Replimune's TUDRIQEV plus nivolumab for advanced melanoma
-
BioKey dismisses auditor Simon & Edward, engages Kreit & Chiu CPA LLP
-
Accuray transfers listing to Nasdaq Capital Market; gets 180-day bid price extension
-
Lulu's Fashion Lounge regains Nasdaq compliance on market value standard
-
Olenox Industries regains Nasdaq compliance after filing delinquent 10-K and 10-Q
-
Upland Software receives Nasdaq deficiency notice for failing $15M MVPHS requirement
-
Genprex regains compliance with Nasdaq minimum bid price requirement
-
Vistagen gets Nasdaq extension to Feb 1, 2027 to cure $1.00 bid price deficiency
-
Chipotle discloses salmonella investigation; proactively removed jalapeños from restaurants
-
VSee Health receives Nasdaq delisting notice; trading to be suspended Aug 6, 2026
-
Sadot Group regains Nasdaq minimum equity compliance; future compliance still at risk
-
Mangoceuticals gets Nasdaq bid-price extension to Feb 1, 2027; notes Nuclea Energy deal
-
CervoMed's neflamapimod gets UK Innovation Passport for DLB treatment
-
AEON Biopharma regains NYSE American listing compliance after $13.6M offering
-
Anteris Technologies obtains court orders to rectify late cleansing notice for 44,068 CDIs
-
Tonix receives FDA alignment on Phase 2 study design for TNX-4800 Lyme disease prevention
-
bioAffinity receives Nasdaq delisting notice for bid price non-compliance; plans appeal
-
Humacyte receives Nasdaq notice of non-compliance with minimum bid price rule
-
Mira Pharmaceuticals receives Nasdaq delisting notice for bid price below $1
-
Upexi receives Nasdaq deficiency notice for bid price below $1.00
-
EMCOR subsidiary receives MSHA imminent danger order at Texas mine; no injuries
-
Traws Pharma receives Nasdaq delisting notice for bid price below $1.00